Cited 0 times in
Influence of ABCC2, SLCO1B1, and ABCG2 Polymorphisms on the Pharmacokinetics of Olmesartan
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박민수 | - |
dc.contributor.author | 정재용 | - |
dc.contributor.author | 조성권 | - |
dc.contributor.author | 김춘옥 | - |
dc.date.accessioned | 2014-12-19T17:02:09Z | - |
dc.date.available | 2014-12-19T17:02:09Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0160-2446 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90655 | - |
dc.description.abstract | This study was designed to determine whether genetic polymorphisms of multidrug-resistant protein 2 (ABCC2), organic anion transporting polypeptide 1B1 (SLCO1B1), and breast cancer resistance protein (ABCG2) have an effect on olmesartan pharmacokinetics in Korean subjects. Sixty-eight healthy male volunteers who participated in previous pharmacokinetics studies of olmesartan medoxomil (single dose, 20 mg or 40 mg) were enrolled. All subjects were analyzed and grouped according to the genotypes of ABCC2, SLCO1B1, and ABCG2. The dose-normalized peak plasma concentration (C(max)) and area under the plasma concentration-time curve (AUCt) values were analyzed. The dose-normalized mean C(max) and AUC(t) in the ABCC2 -24CT genotype group were higher than those in the -24CC genotype group [C(max,dn): CT 26.1 ± 6.5 (ng/mL)/mg versus CC 22.1 ± 6.7 (ng/mL)/mg, P = 0.010, AUC(t,dn): CT 178.7 ± 45.6 (hr·ng(-1)·mL(-1))/mg versus CC 149.9 ± 39.8 (hr·ng(-1)·mL(-1))/mg, P = 0.010]. The difference in AUC(t,dn) between the ABCC2 -1549GG and -1549GA genotype groups was statistically significant [GG 149.0 ± 41.0 (hr·ng(-1)·mL(-1))/mg versus GA 174.1 ± 43.3 (hr·ng(-1)·mL(-1))/mg, P = 0.019]. No significant differences were observed for any other single nucleotide polymorphism in ABCC2, SLCO1B1, or ABCG2. The ABCC2 -24CC genotype group exhibited lower systemic exposure of olmesartan than the -24CT genotype group, whereas no significant differences were observed in the other transporter genotype groups. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | - |
dc.subject.MESH | ATP-Binding Cassette Transporters/genetics* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antihypertensive Agents/administration & dosage | - |
dc.subject.MESH | Antihypertensive Agents/pharmacokinetics | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imidazoles/administration & dosage | - |
dc.subject.MESH | Imidazoles/pharmacokinetics* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Multidrug Resistance-Associated Proteins/genetics* | - |
dc.subject.MESH | Neoplasm Proteins/genetics* | - |
dc.subject.MESH | Olmesartan Medoxomil | - |
dc.subject.MESH | Organic Anion Transporters/genetics* | - |
dc.subject.MESH | Polymorphism, Single Nucleotide | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Solute Carrier Organic Anion Transporter Family Member 1b1 | - |
dc.subject.MESH | Tetrazoles/administration & dosage | - |
dc.subject.MESH | Tetrazoles/pharmacokinetics* | - |
dc.subject.MESH | Young Adult | - |
dc.title | Influence of ABCC2, SLCO1B1, and ABCG2 Polymorphisms on the Pharmacokinetics of Olmesartan | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학) | - |
dc.contributor.googleauthor | Choon O. Kim | - |
dc.contributor.googleauthor | Sung K. Cho | - |
dc.contributor.googleauthor | Eun S. Oh | - |
dc.contributor.googleauthor | Min S. Park | - |
dc.contributor.googleauthor | Jae-Yong Chung | - |
dc.identifier.doi | 22494992 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01468 | - |
dc.contributor.localId | A03709 | - |
dc.contributor.localId | A03829 | - |
dc.contributor.localId | A04735 | - |
dc.relation.journalcode | J01296 | - |
dc.identifier.eissn | 1533-4023 | - |
dc.identifier.pmid | 22494992 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00005344-201207000-00007&LSLINK=80&D=ovft | - |
dc.subject.keyword | olmesartan | - |
dc.subject.keyword | MRP2 | - |
dc.subject.keyword | OATP1B1 | - |
dc.subject.keyword | BCRP | - |
dc.subject.keyword | pharmacokinetics | - |
dc.contributor.alternativeName | Park, Min Soo | - |
dc.contributor.alternativeName | Chung, Jae Yong | - |
dc.contributor.alternativeName | Cho, Sung Kweon | - |
dc.contributor.affiliatedAuthor | Park, Min Soo | - |
dc.contributor.affiliatedAuthor | Chung, Jae Yong | - |
dc.contributor.affiliatedAuthor | Cho, Sung Kweon | - |
dc.citation.volume | 60 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 49 | - |
dc.citation.endPage | 54 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, Vol.60(1) : 49-54, 2012 | - |
dc.identifier.rimsid | 33446 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.